This article is more than 5 years old. Information may no longer be current.

Valeant, Croma reach agreement to expand U.S. Bausch + Lomb portfolio

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

An agreement between Valeant and Croma may provide additional ophthalmic opportunities for Bausch + Lomb’s United States market, according to a Bausch + Lomb press release.

Valeant announced earlier this month that the company acquired hundreds of medical products including viscoelastics, IOLs, surgical instruments, dry eye and anti-inflammatory pharmaceuticals from Croma.

Under the agreement, Valeant will also distribute Croma’s ophthalmology and orthopedics products in Western Europe. Since Croma’s products are not yet available in the U.S., Valeant will need to seek regulatory approval, according to the release.

“Our agreement with Croma gives us access to a rich basket of products on the European market today, as well as others currently in development,” Ari Kellen, MBBCh, MBA, head of U.S. eye health at Bausch + Lomb, said in the press release. “This access is part of our ongoing strategy to grow our ophthalmic business and meet the needs of our U.S. customers.”